Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 25;13(21):6398.
doi: 10.3390/jcm13216398.

Finerenone: A Third-Generation MRA and Its Impact on Cardiovascular Health-Insights from Randomized Controlled Trials

Michael Sabina  1 , Jennifer Trube  1 , Shrinand Shah  1 , Andrew Lurie  1 , Mason Grimm  1 , Anas Bizanti  1
Affiliations
Review

Finerenone: A Third-Generation MRA and Its Impact on Cardiovascular Health-Insights from Randomized Controlled Trials

Michael Sabina et al. J Clin Med. .

Abstract

Introduction: Finerenone, a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), offers a targeted approach to managing cardiovascular outcomes, particularly in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Unlike traditional MRAs such as spironolactone and eplerenone, which can cause off-target hormonal side effects and hyperkalemia, Finerenone selectively binds to mineralocorticoid receptors, reducing these risks. Recent randomized controlled trials have demonstrated Finerenone's potential to improve cardiovascular outcomes, making it a promising alternative in the management of heart failure and other cardiovascular conditions associated with CKD and T2D. Methods: We conducted a scoping review using PRISMA guidelines. A search for "Finerenone" in the PubMed, Embase, and Cochrane Library databases included randomized controlled trials (RCTs), post hoc analyses, and relevant meta-analyses on cardiovascular outcomes. Data were synthesized narratively, assessing study quality through strengths and limitations. Discussion: Finerenone has shown significant benefits and a superior safety profile compared with traditional MRAs like spironolactone and eplerenone in managing CKD, T2D, and heart failure. It effectively reduces cardiovascular and renal events while minimizing risks such as hyperkalemia and hormonal side effects associated with steroidal MRAs. Future studies, including the REDEFINE-HF, FINALITY-HF, and CONFIRMATION-HF trials, will further explore Finerenone's potential across diverse heart failure phenotypes, including its role in heart failure with mildly reduced and preserved ejection fractions, potentially establishing it as a cornerstone therapy in heart failure management. Conclusions: Finerenone represents a significant advancement in MRA therapy, offering enhanced safety and efficacy in managing cardiovascular outcomes in CKD and T2D patients. The current evidence supports its use as a promising alternative to traditional MRAs, particularly in patients intolerant to steroidal MRAs. Further trials are needed to fully establish its potential across diverse patient populations, including those with varying heart failure phenotypes.

Keywords: eplerenone; finerenone; heart failure; spironolactone; steroidal mineralocorticoid receptor antagonist; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram.
Figure 2
Figure 2
Spironolactone’s action on mineralocorticoid receptors and androgen receptors. Legend: MR = Mineralocorticoid receptor.
Figure 3
Figure 3
MRA’s action on mineralocorticoid and androgen receptors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Jr., Colvin M.M., Drazner M.H., Filippatos G.S., Fonarow G.C., Givertz M.M., et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J. Am. Coll. Cardiol. 2017;70:776–803. - PubMed
    1. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K., Falk V., Filippatos G., Fonseca C., Gomez-Sanchez M.A., et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012;33:1787–1847. doi: 10.1093/eurheartj/ehs104. - DOI - PubMed
    1. Young D.B., Smith M.J., Jr., Jackson T.E., Scott R.E. Multiplicative interaction between angiotensin II and K concentration in stim-ulation of aldosterone. Am. J. Physiol. 1984;247:E328. - PubMed
    1. Ghose R.P., Hall P.M., Bravo E.L. Medical management of aldosterone-producing adenomas. Ann. Intern. Med. 1999;131:105–108. doi: 10.7326/0003-4819-131-2-199907200-00005. - DOI - PubMed
    1. Levac D., Colquhoun H., O’Brien K.K. Scoping studies: Advancing the methodology. Implement. Sci. 2010;5:69. doi: 10.1186/1748-5908-5-69. - DOI - PMC - PubMed

LinkOut - more resources